What is the Origin of GLP-1/GIP Agonist?

The development of these dual agonists arose from the established success of single GLP-1 receptor agonists and the subsequent discovery that GIP, the original incretin, possesses complementary metabolic effects. Scientists hypothesized that targeting both pathways could synergistically improve insulin secretion and suppress appetite. The term "agonist" denotes that the drug activates the receptor, mimicking the effect of the endogenous hormones.

What is the Mechanism of GLP-1/GIP Agonist?

When administered, the dual agonist binds to both GLP-1 and GIP receptors on target cells. Activation of the GLP-1 receptor stimulates insulin release from the pancreas in a glucose-dependent manner, inhibits glucagon secretion, and slows gastric emptying. Concurrently, GIP receptor activation further enhances insulin secretion and may improve beta-cell survival. The combined action centrally regulates appetite in the hypothalamus, leading to reduced caloric intake and improved metabolic parameters.

GLP-1/GIP Agonist

Meaning

A GLP-1/GIP agonist is a novel class of pharmaceutical agents that simultaneously activate the receptors for two distinct incretin hormones: Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP). These dual-acting compounds represent a significant advance in the pharmacological management of type 2 diabetes and obesity. By engaging both receptor pathways, they offer enhanced efficacy in improving glucose homeostasis and promoting substantial weight reduction.